Fig. 2.
Overall survival from the time of inclusion in the LNH-87 trial of patients with ALCL according to immunophenotype: B-cell (n = 56), T-cell (n = 49), and null type (n = 33). P = .83.
Overall survival from the time of inclusion in the LNH-87 trial of patients with ALCL according to immunophenotype: B-cell (n = 56), T-cell (n = 49), and null type (n = 33). P = .83.
